title: Polymporphism of monocyte chemoattractant protein 1 (MCP1 -2518 A/G) and responsiveness to hepatitis B vaccination in hemodialysis patients.
abstract: BACKGROUND
  Monocyte chemoattractant protein 1 (MCP‑1) is involved in the pathogenesis of renal diseases, diabetes, and hepatitis B virus (HBV) clearance.
  
  
  OBJECTIVE
  The aim of the study was to evaluate the distribution of MCP1-2518 A/G (rs1024611) polymorphic variants in patients on hemodialysis (HD) with respect to their responsiveness to hepatitis B vaccination.
  
  
  METHODS
  Patients on HD, never infected with HBV, were enrolled into the study after receiving an appropriate hepatitis B vaccine. The HD group consisted of 601 individuals who responded to vaccination with anti‑HBs titer exceeding 10 IU/l considered as protective and 153 nonresponders, in whom no adequate response was observed (anti‑HBs, ≤10 IU/l). There were 175 diabetic patients among responders and 47 diabetic patients among nonresponders. Healthy subjects served as controls (n = 437). MCP1 genotyping was determined by polymerase chain reaction-restriction fragment length polymorphism.
  
  
  RESULTS
  The distribution of MCP1 rs1024611 polymorphic variants in controls was as follows: AA, 51%; AG, 41%; GG, 8%. There were no significant differences (P >0.05) in MCP1 distribution between the study groups and controls, independently of the occurrence of diabetes and responsiveness to hepatitis B vaccination. HD groups that were identified based on diabetic status and responsiveness to hepatitis B vaccination did not differ in MCP1 distribution.
  
  
  CONCLUSIONS
  MCP10-2518 A/G polymorphism is not associated with responsiveness to hepatitis B vaccination in patients on HD, independently of whether they have diabetes or not.
authors.forename: Alicja E
authors.initials: AE
authors.lastname: Grzegorzewska
authors.forename: Dominik
authors.initials: D
authors.lastname: Pajzderski
authors.forename: Anna
authors.initials: A
authors.lastname: Sowińska
authors.forename: Paweł P
authors.initials: PP
authors.lastname: Jagodziński
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D018932:Chemokine CCL2 / Q000097:blood / Q000235:genetics*; D003920:Diabetes Mellitus / Q000097:blood*; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000097:blood*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D006435:Renal Dialysis; D014611:Vaccination
chemical_list: D015415:Biomarkers; D018932:Chemokine CCL2; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines